Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

255
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
255
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

869
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
869
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

290
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
290
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

802
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
802

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and preclinical evaluation of an asialoglycoprotein receptor 1-targeted antibody-drug conjugate in hepatic inflammation.

International journal of biological macromolecules·2026
Same author

Structural and functional characterization of human kallistatin.

Biochemistry and biophysics reports·2026
Same author

Liver and kidney cross talk: liver-derived bile acids and kidney water retention.

American journal of physiology. Endocrinology and metabolism·2026
Same author

Can the Contact System be the Missing Link in Immune Checkpoint Inhibitors Associated Thromboinflammation?

Hamostaseologie·2026
Same author

The NKp44-1 Isoform Is an Activating Receptor for PDGF-DD Expressed on Natural Killer Cells.

Cancers·2026
Same author

Contact Activation Is Alleviated by Testosterone Replacement Therapy in Klinefelter Syndrome: Evidence of Hormonal and Metabolic Modulation.

Andrology·2026

Related Experiment Video

Updated: Jan 13, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.5K

Urokinase Promotes Redundantly Intratubular C3a-Formation But Not ENaC-Driven Hypertension in DOCA/Salt Kidney

Marie Lykke Bach1, Camilla Enggaard1, Sai Sindhu Thangaraj1

  • 1University of Southern Denmark, Department of Molecular Medicine - Cardiovascular and Renal Research Unit, Odense M, Denmark (M.L.B., C.E., P.S., B.L.J.).

Hypertension (Dallas, Tex. : 1979)
|January 8, 2026
PubMed
Summary

Urokinase-type plasminogen activator (uPA) does not drive hypertension or kidney injury in DOCA-salt models. However, uPA-generated plasmin influences specific cytokines and complement activation in chronic kidney disease.

Keywords:
albuminuriaaldosteroneblood pressurechronic kidney diseaseinflammation

More Related Videos

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.8K
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

39.0K

Related Experiment Videos

Last Updated: Jan 13, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.5K
Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.8K
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

39.0K

Area of Science:

  • Nephrology
  • Molecular Biology
  • Immunology

Background:

  • Urokinase-type plasminogen activator (uPA) inhibitors help manage salt retention and inflammation in acute kidney diseases.
  • This study investigates the role of uPA in hypertension and inflammation in chronic kidney injury (CKI) with albuminuria.

Purpose of the Study:

  • To determine if uPA contributes to hypertension and complement-dependent inflammation in chronic kidney injury.
  • To examine the impact of uPA on kidney injury markers and macrophage polarization.

Main Methods:

  • Wild-type and uPA knockout mice were subjected to unilateral nephrectomy and deoxycorticosterone acetate (DOCA)-salt treatment.
  • Measurements included glomerular filtration rate, arterial blood pressure, urine analysis (albumin, electrolytes, kidney injury markers), and kidney tissue analysis (cytokines, inflammation, macrophage polarization).

Main Results:

  • DOCA-salt treatment increased diuresis, albuminuria, and tubular injury markers, independent of genotype.
  • While blood pressure elevation was similar in both genotypes, uPA knockout mice showed reduced urinary plasmin, C3, and C3a levels.
  • uPA knockout mice exhibited reduced levels of certain kidney inflammatory cytokines (TNF, IP-10) compared to wild-type mice.

Conclusions:

  • uPA is not essential for filtration barrier injury, GFR decline, or hypertension in DOCA-salt-induced kidney injury.
  • uPA, via plasmin generation, influences specific cytokines and complement activation, contributing to inflammation in chronic kidney injury.